Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025. The company posted significant improvements in net income and earnings per share compared to the prior year.
For the fourth quarter ended December 31, 2025, Bio-Rad reported net income of $720.0 million, a turnaround from the net loss of $715.8 million in the same period of 2024. Earnings per share were $26.65, compared to a loss of $25.57 per share a year earlier.
For the full year 2025, the company achieved net income of $759.9 million, versus a net loss of $1,844.2 million in 2024. Earnings per share for the full year were $27.85, significantly higher than the loss of $65.36 per share in the prior year.
The strong financial performance was driven by gains from changes in the fair market value of equity securities and loan receivables during 2025, compared to substantial losses recorded in the previous year.
Net sales for the fourth quarter rose to $693.2 million from $667.5 million a year ago, while full-year net sales increased to $2,583.2 million from $2,566.5 million in 2024.
BIO is currently trading after market at $256.54 down $35.88 or 2.27 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.